-
Xanomeline (developmental code name LY-246,708) is a
small molecule muscarinic acetylcholine receptor agonist that was
synthesized in a
collaboration between...
-
Xanomeline/trospium chloride, sold
under the
brand name Cobenfy, is a fixed-dose
combination medication used for the
treatment of schizophrenia. It contains...
- promising. The dual M1, M4
agonist xanomeline has been
proposed as a
potential treatment for schizophrenia.
Xanomeline/trospium
chloride was
approved in...
-
partial agonist.
Xanomeline/trospium
chloride (Cobenfy) - A fixed-dose
combination of
xanomeline and
trospium chloride.
Xanomeline is a functionally...
- SKF-89976A, tiagabine, and CI-966.
Xanomeline, the anti-schizophrenia
component in the
approved drug
xanomeline/trospium chloride, also has structural...
-
mouse data
suggests M4
receptors drive the
antipsychotic activity of
xanomeline, with M1
receptors believed to
contribute to GI side effects. In June...
- long-term
adherence to treatment. The fixed-dose
combination medication xanomeline/trospium
chloride (Cobenfy) was
approved for
medical use in the United...
-
approved the drug
KarXT (Cobenfy),
which is a
combination drug that
combines xanomeline (a
preferentially acting M1/M4
muscarinic acetylcholine receptor agonist)...
-
memory deficits. Structurally, it is a
tetrahydropyridine similarly to
xanomeline and milameline.
Itameline was
first described in the
scientific literature...
-
Vedaclidine VU-0029767 VU-0090157 VU-0152099 VU-0152100 VU-0238429 WAY-132,983
Xanomeline YM-796
Antagonists 3-Quinuclidinyl
benzilate 4-DAMP
Aclidinium bromide...
